Ultherapy Candidates and Contraindications

Ultherapy® (MFU-V) candidates are typically 30–65 with mild-to-moderate facial laxity (Merz Aesthetics Scale ~2–3), good baseline skin quality, and realistic expectations. Severe laxity (Grade 4) is better served by surgical consultation. Absolute contraindications include pregnancy, active infection in the treatment area, permanent fillers in the focal path, keloid history, and uncontrolled anticoagulation. Candidacy is decided in person.

Ultherapy works well for a defined band of patients. For others it is less suited, and sometimes outright contraindicated. The published consensus is that MFU-V is best suited for patients with mild-to- moderate skin and soft tissue laxity; patients with severe laxity and marked platysmal banding are usually better served by surgical consultation^[1]. This page describes who tends to do well, who should consider an alternative, and which conditions make MFU-V unsafe.

Good candidates

The clearest indication for MFU-V is mild to moderate laxity in patients who still have reasonable skin quality and bony support. Practically, this maps to patients roughly thirty to sixty-five years old who have noticed:

• A softening of the jawline contour with early jowl formation, but no significant submandibular skin redundancy.
• Mild laxity of the neck — typically across the lateral neck and upper submental triangle — without prominent platysmal banding.
• Brow descent producing a tired or heavy upper-lid appearance, again in the mild to moderate range.
• Etched horizontal lines on the décolletage from sun exposure and sleeping position.

Realistic expectations are part of the candidacy assessment. A good candidate understands that MFU-V is a tightening and modest lifting treatment, that the visible change emerges over two to three months, and that results last one to two years rather than indefinitely. Patients expecting a surgical-grade lift from a non-surgical session are poor candidates, not because of their anatomy but because they are setting themselves up for disappointment.

Less-suited candidates

Patients with advanced laxity, significant skin redundancy, or pronounced platysmal banding are usually better served by surgical consultation. MFU-V can still offer a modest improvement in these cases, but the gap between what the patient sees in the mirror and what the patient hoped for after treatment is large. A dermatologist will sometimes recommend a combination plan — for example, MFU-V plus thread lift, or MFU-V as a maintenance treatment after surgery — but will not suggest MFU-V alone as a substitute for a procedure the patient really needs.

Patients with very thin, atrophic, or sun-damaged skin without meaningful underlying laxity also tend not to benefit. The collagen remodelling response that drives MFU-V results depends on a healthy dermal fibroblast population; severely photodamaged skin may need a different first step, such as a structured topical and resurfacing protocol, before MFU-V is a useful next move.

Absolute and relative contraindications

These are the conditions that should stop or modify a planned treatment:

• Pregnancy or breastfeeding. No safety data supports MFU-V in this population. Treatment is deferred.
• Active infection in the treatment area. Acne flares, impetigo, herpes simplex outbreaks. Treatment is postponed until the area is clear.
• Open wounds or recent surgical incisions in the zone. MFU-V is delayed until tissue healing is complete, typically at least three months post-surgery, longer for major work.
• Implants in the planned focal path. Metallic implants, permanent dermal fillers (silicone, PMMA), large permanent threads, and dental implants near the treatment area require careful zone planning. Temporary HA fillers placed recently are usually a relative contraindication — the dermatologist may defer treatment or adjust the zone map.
• Keloid or hypertrophic scarring history. The thermal injury created by MFU-V is small and confined, but patients with strong keloid history are evaluated cautiously and may have a test area performed first.
• Active systemic autoimmune disease affecting skin. Lupus, dermatomyositis, and other conditions that affect dermal healing require specialist involvement before treatment.
• Anticoagulation that cannot be safely paused. While MFU-V is not surgical and bleeding is minimal, the consultation will review medication context. Patients on warfarin, DOACs, or clinically indicated antiplatelet therapy require a case-by-case decision in coordination with the prescribing physician.

Combination treatments — what the evidence supports

Many patients ask whether MFU-V can be sequenced with other dermatology treatments. Published safety data is reassuring. A retrospective review of 101 subjects who received MFU-V combined with botulinum toxin and/or temporary or semi-permanent dermal fillers within six months reported a 7% adverse event rate (bruising, swelling, paresthesia, one herpes simplex reactivation) — consistent with the individual safety profiles of each treatment^[2]. A separate study of suspension threads combined with MFU-V found preserved structural integrity of poly-L-lactic acid, polyethylene and polyamide threads, and greater neocollagenesis at three months when threads were combined with MFU-V compared to MFU-V alone^[3].

What the consultation actually checks

A proper consultation is not a sales conversation. The dermatologist will examine the face and neck under good light, palpate the submental and jawline tissue to assess laxity grade and skin thickness, ask about prior cosmetic treatments (including those the patient may have forgotten — threads from years ago, permanent fillers from another country), review medications, and consider the patient's photographs at rest and with animation. If a different modality is a better fit, that is what will be recommended.

Patients travelling from outside Korea can streamline the visit by sending photographs and a medication list ahead of time. The clinic can confirm whether MFU-V is a reasonable plan before the patient arrives. To start that process you can book directly through Delight Dermatology Clinic using the main reservation page; international consultation requests go through the same channel.

Risks and contraindications

Ultherapy® (MFU-V) is well tolerated when performed by a trained dermatologist, but it is not risk-free. Common transient effects include redness and warmth (resolves in hours), mild swelling at 1–3 days, and occasional bruising at the jawline. Rare adverse events include temporary numbness in a specific facial zone, transient weakness of a facial muscle, small areas of skin sensitivity, and — in patients with permanent dermal filler in the focal path — focal nodules or fat atrophy. In a 52-patient open-label trial across Fitzpatrick III–VI skin, the three reported adverse events resolved by day 90 without sequelae^[4].

Absolute contraindications: pregnancy and breastfeeding, active infection in the treatment area, open wounds or recent surgical incisions in the zone, and significant immunosuppression. Relative contraindications discussed at consultation: keloid history, autoimmune skin disease, recent dermal fillers, and clinically indicated anticoagulation that cannot be safely paused.

Note: this page is general information. Whether MFU-V is right for any individual patient can only be decided by a qualified dermatologist who has examined the patient.

Medically reviewed by a Korean Board-Certified Dermatologist (AAD International Fellow · ASLMS member). Last reviewed 2026-06-08.